Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024603 · ClinicalTrials.gov registry record · NA
Individualized Treatments in Adults With Relapsed/Refractory Cancers
A NA study of Refractory Cancer and Relapsed Cancer, sponsored by Case Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT06024603 is a NA study of Refractory Cancer and Relapsed Cancer that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 36 participants, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06024603, a NA study of Refractory Cancer and Relapsed Cancer, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Drug Sensitivity Test (DST)
Study Locations (2)
Florida
- Florida International University - Miami
- Lerner College of Medicine, Cleveland Clinic Florida - Weston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06024603
The ClinicalTrials.gov registry entry for NCT06024603 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 15 other Refractory Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Refractory Cancer appearing as the primary indexed condition, and to 1 intervention - of which Drug Sensitivity Test (DST) is the first listed.
NCT06024603 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06024603 about?
NCT06024603 is a clinical study titled "Individualized Treatments in Adults With Relapsed/Refractory Cancers". A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type...
What is the current status of trial NCT06024603?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2023-11-20. Estimated completion is 2026-06.
What conditions does trial NCT06024603 study?
This clinical trial studies the following conditions: Refractory Cancer, Relapsed Cancer.
What interventions are being tested in trial NCT06024603?
The interventions under investigation include: Drug Sensitivity Test (DST) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06024603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06024603 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.